Surface Exposure of PEG and Amines on Biodegradable Nanoparticles as a Strategy to Tune Their Interaction with Protein-Rich Biological Media.
PEGylated nanoparticles
biological barriers
cationic nanoparticles
proteins
Journal
Nanomaterials (Basel, Switzerland)
ISSN: 2079-4991
Titre abrégé: Nanomaterials (Basel)
Pays: Switzerland
ID NLM: 101610216
Informations de publication
Date de publication:
20 Sep 2019
20 Sep 2019
Historique:
received:
19
08
2019
revised:
10
09
2019
accepted:
17
09
2019
entrez:
25
9
2019
pubmed:
25
9
2019
medline:
25
9
2019
Statut:
epublish
Résumé
Nanoparticles (NPs) based on amphiphilic block copolymers of polyethylene glycol (PEG) and biodegradable polyesters are of particular current interest in drug nanodelivery due to their easily manipulated properties. The interaction of these NPs with biological environments is highly influenced by shell features, which drive biological identity after administration. To widen the strategies available for tuning particle surface chemistry, here we developed a panel of amine-bearing PEGylated NPs with a poly(ε-caprolactone) (PCL) core for the delivery of lipophilic drugs, and investigated the impact of NP modifications on their interaction with abundant circulating proteins (human serum albumin-HSA-and mucin), as well as their transport through biological barriers (artificial mucus-AM, extracellular matrix-ECM). We prepared NPs based on a diamino-terminated PCL (amine-NPs) and its mixture with PEG-PCL copolymers (amine/PEG-NPs) at different PEG molecular weights by nanoprecipitation, as well as corresponding NPs of PEG-PCL (PEG-NPs). The presence of an amine-bearing polymer resulted in NPs with a net positive charge and a zeta potential dependent on the length of PEG in the copolymer. Amine/PEG-NPs had a larger fixed aqueous layer thickness as compared to PEG-NPs, suggesting that PEG conformation is affected by the presence of positive charges. In general, amine-bearing NPs promptly interacted with the dysopsonic protein HSA, due to electrostatic interactions, and lose stability, thereby undergoing time-related aggregation. On the other hand, amine/PEG-NPs interaction with mucin induced switching to a negative surface charge but did not alter the quality of the dispersion. The transport kinetics of NPs through a layer of artificial mucus and tumor extracellular matrix was studied by means of fluorescent NPs based upon FRET. Amine/PEG-NPs did not cross the ECM, but they were promptly transported through the AM, with swifter transport noted at increasing MWs of PEG in the copolymer. Finally, we demonstrated that all the different NP types developed in this study are internalized by human monocytes and, despite the positive charge, they did not induce a measurable inflammatory effect. In conclusion, we showed that the concurrent presence of both PEG and amine groups on NP surface is a promising strategy for directing their interaction with body compartments. While PEG-NPs are confirmed for their capacity to cross ECM-like compartments, amine/PEG-NPs are revealed as a powerful platform to widen the arsenal of nanotools available for overcoming mucus-covered epithelia.
Identifiants
pubmed: 31547212
pii: nano9101354
doi: 10.3390/nano9101354
pmc: PMC6835417
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : IG2014 n.15764
Références
Pharm Dev Technol. 2013 May-Jun;18(3):730-5
pubmed: 23033924
Biomacromolecules. 2017 May 8;18(5):1449-1459
pubmed: 28328191
ACS Nano. 2015 May 26;9(5):5104-16
pubmed: 25894117
Expert Opin Emerg Drugs. 2015;20(4):531-6
pubmed: 26583759
J Mater Chem B. 2018 Oct 7;6(37):5922-5930
pubmed: 32254712
Ann Biomed Eng. 2013 Jan;41(1):68-77
pubmed: 22855118
J Control Release. 2012 Jan 10;157(1):149-59
pubmed: 21864595
J Control Release. 2018 May 10;277:126-141
pubmed: 29534890
Expert Opin Drug Deliv. 2010 Jul;7(7):795-809
pubmed: 20446858
ACS Nano. 2015 Sep 22;9(9):9217-27
pubmed: 26301576
Nanoscale. 2014 Mar 7;6(5):2782-92
pubmed: 24463404
J Control Release. 2017 Aug 28;260:46-60
pubmed: 28536049
Theranostics. 2016 Aug 07;6(11):1887-98
pubmed: 27570558
Adv Drug Deliv Rev. 2018 Jan 15;124:125-139
pubmed: 28882703
Acc Chem Res. 2014 Aug 19;47(8):2651-9
pubmed: 25014679
Int J Pharm. 2006 Oct 31;324(1):56-66
pubmed: 16920288
Angew Chem Int Ed Engl. 2017 Jun 12;56(25):7088-7092
pubmed: 28455941
Nanomedicine (Lond). 2016 Jan;11(1):81-100
pubmed: 26653875
Eur J Pharm Sci. 2018 Jan 1;111:177-185
pubmed: 28966100
Colloids Surf B Biointerfaces. 2015 Nov 1;135:717-725
pubmed: 26340361
Proc Natl Acad Sci U S A. 2008 May 6;105(18):6596-601
pubmed: 18445654
Nat Nanotechnol. 2012 Dec;7(12):779-86
pubmed: 23212421
ACS Appl Mater Interfaces. 2018 Apr 4;10(13):10678-10687
pubmed: 29473725
J Pharm Sci. 2006 Sep;95(9):1873-87
pubmed: 16795003
Expert Opin Drug Deliv. 2005 Sep;2(5):843-54
pubmed: 16296782
Semin Immunol. 2017 Dec;34:33-51
pubmed: 28869063
Polymers (Basel). 2016 Mar 17;8(3):
pubmed: 30979183
Curr Top Med Chem. 2014;14(9):1097-114
pubmed: 24678711
Nat Rev Drug Discov. 2003 Mar;2(3):214-21
pubmed: 12612647